Insights in to the pathogenesis of axial spondyloarthropathy based on gene expression profiles
Authors:
- Srilakshmi M SharmaSSSrilakshmi M Sharma
- Dongseok ChoiDCDongseok Choi
- Stephen R PlanckSPStephen R Planck
- Christina A HarringtonCHChristina A Harrington
- Carrie R AustinCACarrie R Austin
- Jinnell A LewisJLJinnell A Lewis
- Tessa N DiebelTDTessa N Diebel
- Tammy M MartinTMTammy M Martin
- Justine R SmithJSJustine R Smith
- James T RosenbaumJRJames T Rosenbaum
Open Access
- 9 November 2009
- journal article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 11 (6) , R168
Abstract
Introduction: Axial spondyloarthropathy (SpA) is a group of inflammatory diseases, with ankylosing spondylitis as the prototype. SpA affects the axial skeleton, entheses, joints and, at times, the eyes. This study tested the hypothesis that SpA is characterized by a distinct pattern of gene expression in peripheral blood of affected individuals compared with healthy controls. Methods: High-density, human GeneChip® probe arrays were used to profile mRNA of peripheral blood cells from 18 subjects with SpA and 25 normal individuals. Samples were processed as two separate sets at different times (11 SpA + 12 control subjects in primary set (Set 1); 7 SpA+ 13 control subjects in the validation set (Set 2)). Blood samples were taken at a time when patients were not receiving systemic immunomodulatory therapy. Differential expression was defined as a 1.5-fold change with a q value < 5%. Gene ontology and pathway information were also studied. Results: Signals from 134 probe sets (representing 95 known and 12 unknown gene transcripts) were consistently different from controls in both Sets 1 and 2. Included among these were transcripts for a group of 20 genes, such as interleukin-1 (IL-1) receptors 1 and 2, Nod-like receptor family, pyrin domain containing 2 (NLRP2), secretory leukocyte peptidase inhibitor (SLPI), secreted protein acidic and rich in cysteine (SPARC), and triggering receptor expressed on myeloid cells 1 (TREM-1) that are clearly related to the immune or inflammatory response and a group of 4 transcripts that have a strong role in bone remodeling. Conclusions: Our observations are the first to implicate SPARC, SLPI, and NLRP2, a component of the innate immune system, in the pathogenesis of SpA. Our results also indicate a possible role for IL-1 and its receptors in SpA. In accord with the bone pathology component of SpA, we also found that expression levels of transcripts reflecting bone remodeling factors are also distinguishable in peripheral blood from patients with SpA versus controls. These results confirm some previously identified biomarkers implicated in the pathogenesis of SpA and also point to novel mediators in this disease.Keywords
This publication has 28 references indexed in Scilit:
- Application of Biostatistics and Bioinformatics Tools to Identify Putative Transcription Factor-Gene Regulatory Network of Ankylosing Spondylitis and SarcoidosisCommunications in Statistics - Theory and Methods, 2009
- Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1): a new mediator involved in early ankylosing spondylitis.2008
- Eating bone or adding it: the Wnt pathway decidesNature Medicine, 2007
- Ankylosing spondylitis and bowel diseaseBest Practice & Research Clinical Rheumatology, 2006
- Inflammatory back pain in ankylosing spondylitis: A reassessment of the clinical history for application as classification and diagnostic criteriaArthritis & Rheumatism, 2006
- Accelerated dendritic-cell migration and T-cell priming in SPARC-deficient miceJournal of Cell Science, 2005
- PAN1/NALP2/PYPAF2, an Inducible Inflammatory Mediator That Regulates NF-κB and Caspase-1 Activation in MacrophagesJournal of Biological Chemistry, 2004
- Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupusProceedings of the National Academy of Sciences, 2003
- A 588-gene microarray analysis of the peripheral blood mononuclear cells of spondyloarthropathy patientsRheumatology, 2002
- Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signallingNature, 2002